Cigall Kadoch, PhD
Job Title
Principal Investigator, Pediatric Oncology, Dana-Farber Cancer Institute
Co-Director, Epigenomics Program, Broad Institute of MIT and Harvard
Speaker Bio
Cigall Kadoch, Ph.D., is an Associate Professor of Pediatric Oncology at the Dana-Farber Cancer Institute, Affiliate Faculty of Biological Chemistry and Molecular Biology at Harvard Medical School, and Institute Member and Epigenomics Program Co-Director at the Broad Institute of MIT and Harvard. She is also the scientific founder of Foghorn Therapeutics in Cambridge, MA.
She established her independent laboratory in 2014, at age 28, one of the youngest scientists ever appointed to the Harvard Medical School faculty, immediately following completion of her Ph.D. studies in Cancer Biology at Stanford University. She has quickly become a leading expert in chromatin and gene regulation and she is internationally recognized for her groundbreaking studies in these areas. Specifically, her laboratory studies the structure and function of chromatin remodeling complexes, large protein complexes in the nucleus of cells that regulate genomic architecture. Intriguingly, recent sequencing efforts have unmasked the major, previously unappreciated contribution of these chromatin regulatory complexes to human disease. The genes encoding subunits of such complexes are mutated in over 25% of human cancers and in neurodevelopmental conditions such as intellectual disability and autism-spectrum disorders, bringing these important regulators to the forefront of attention.
Dr. Kadoch has received numerous prestigious awards and research grants to support her academic laboratory at Harvard, including the NIH Director’s New Innovator Award, the Pew Scholar Award, the American Cancer Society Research Scholar Award, and, most recently, the American Association for the Advancement of Science (AAAS) Martin and Rose Wachtel Cancer Research Prize. Additionally, she was named to the Forbes 30 Under 30 list, MIT Technology Review 35 Innovators Under 35, Popular Science Brilliant 10, and Business Insider Top 30 Young Leaders in Biopharma.
She established her independent laboratory in 2014, at age 28, one of the youngest scientists ever appointed to the Harvard Medical School faculty, immediately following completion of her Ph.D. studies in Cancer Biology at Stanford University. She has quickly become a leading expert in chromatin and gene regulation and she is internationally recognized for her groundbreaking studies in these areas. Specifically, her laboratory studies the structure and function of chromatin remodeling complexes, large protein complexes in the nucleus of cells that regulate genomic architecture. Intriguingly, recent sequencing efforts have unmasked the major, previously unappreciated contribution of these chromatin regulatory complexes to human disease. The genes encoding subunits of such complexes are mutated in over 25% of human cancers and in neurodevelopmental conditions such as intellectual disability and autism-spectrum disorders, bringing these important regulators to the forefront of attention.
Dr. Kadoch has received numerous prestigious awards and research grants to support her academic laboratory at Harvard, including the NIH Director’s New Innovator Award, the Pew Scholar Award, the American Cancer Society Research Scholar Award, and, most recently, the American Association for the Advancement of Science (AAAS) Martin and Rose Wachtel Cancer Research Prize. Additionally, she was named to the Forbes 30 Under 30 list, MIT Technology Review 35 Innovators Under 35, Popular Science Brilliant 10, and Business Insider Top 30 Young Leaders in Biopharma.
Speaking At
